RE: Gamechanging RNS20 Sep 2021 12:25
AT278 has the potential to disrupt the market for insulin treatment in people with diabetes, as the first concentrated, yet rapid acting, insulin - a critical enabler in the development of next generation miniaturised insulin delivery systems.